TechnoGenesys, Inc. is focused on commercialization of a novel anti-cancer inhibitor (R)-9b which has `dual' properties: an Androgen receptor (AR) antagonists with immune-regulatory activity
The Phase I clinical trial will start in early 2025
cAstration-resistant prostate cancer (crpc)
Non-Small Cell Lung Cancers (NSCLC)
Triple negative breast cancer (TNBC)
TechnoGenesys, Inc. is also committed to provide the novel companion diagnostics (CDx) that accurately predict response to treatment with inhibitor (R)-9b, in a `personalized medicine’ approach
